Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly

American Journal of Medicine

Volumn 114, Issue 3, 2003, Pages 180-187

  Cohen, Harvey Jay ^a,b   Harris, Tamara ^c   Pieper, Carl F ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; INTERLEUKIN 6;

AGED; ARTICLE; BLOOD CLOTTING; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HUMAN; INFLAMMATION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MISCELLANEOUS NAMED GROUPS; MORTALITY; NORMAL VALUE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SENESCENCE;

EID: 0037440670     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01484-5     Document Type: Article

References (50)

1. Fried L.P., Walston J. Frailty and failure to thrive. Hazzard W.R., Blass J.P., Ettinger W.H., et al. Principles of Geriatric Medicine and Gerontology. 4th ed:1999;1387-1402 McGraw Hill, New York.
2. Hamerman D. Toward an understanding of frailty. Ann Intern Med. 130:1999;945-950.
3. Cohen H.J. In search of the underlying mechanisms of frailty [editorial]. J Gerontol Med Sci. 55A:2000;M706-M708.
4. Hamerman D., Berman J.W., Albers G.W., et al. Emerging evidence for inflammation in conditions frequently affecting older adults: report of a symposium. J Am Geriatr Soc. 47:1999;1016-1025.
5. Currie M.S., Rao K.M.K., Blazer D.G., Cohen H.J. Age and functional correlations of markers of coagulation and inflammation in the elderly functional implications of elevated crosslinked fibrin degradation products (D-dimers) . J Am Geriatr Soc. 42:1994;738-742.
6. Cohen H.J., Pieper C.F., Harris T., et al. The association of plasma interleukin-6 levels with functional disability in community-dwelling elderly. J Gerontol Med Sci. 52A:1997;M201-M208.
7. Pieper C.F., Rao K.M.K., Currie M.S., et al. Age, functional status and racial differences in plasma D-dimer levels in community-dwelling elders. J Gerontol Med Sci. 55A:2000;M649-M657.
8. Lindahl B., Toss H., Siegbahn A., et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med. 343:2000;1139-1147.
9. Rader D.J. Inflammatory markers of coronary risk. N Engl J Med. 343:2000;1179-1182.
10. Ross R. Atherosclerosis an inflammatory disease . N Engl J Med. 340:1999;115-126.
11. Tracy R.P., Psaty B.M., Macy E., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 17:1997;2167-2176.
12. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 340:1999;448-454.
13. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:2000;836-843.
14. Cushman M., Lemaitre R.N., Kuller L.H., et al. Fibrinolytic activation markers predict myocardial infarction in the elderly the Cardiovascular Health Study . Arterioscler Thromb Vasc Biol. 19:1999;493-498.
15. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA. 279:1998;1477-1482.
16. Kohler H.D., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 342:2000;1792-1801.
17. Ridker P.M., Hennekens C.H., Cerskus A., Stampfer M.J. Plasma concentration of cross- linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 90:1994;2236-2240.
18. Jenkins G., Seiffert D., Parmer R., Miles L. Regulation of plasminogen gene expression by interleukin-6. Blood. 89:1997;2394-2403.
19. Kazura J.W., Wenger J.D., Salata R.A., et al. Modulation of polymorphonuclear leukocyte microbial activity and oxidative-metabolism of fibrinogen degradation product D and product E. J Clin Invest. 83:1989;1916-1924.
20. Edgington T.S., Curtiss L.K., Plow E.F. A linkage between hemostatic and immune systems embodied in the fibrinolytic release of lymphocyte suppressive peptides. J Immunol. 134:1985;471-477.
21. Opal S.M. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med. 28:(Suppl):2000;S77-S80.
22. Ferrucci L., Harris T.B., Guralnik J.M., et al. Serum interleukin-6 level and the development of disability in older persons. J Am Geriatr Soc. 47:1999;639-646.
23. Kuller L.H. Serum levels of interleukin-6 and development of disability in older persons [editorial]. J Am Geriatr Soc. 47:1999;755-756.
24. Harris T.B., Ferrucci L., Tracy R.P., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 106:1999;506-512.
25. Cornoni-Huntley J., Ostfeld A.M., Taylor J.O., et al. Established populations for epidemiologic studies of the elderly: study design and methodology. Aging Clin Exp Res. 5:1993;27-37.
26. Cornoni-Huntley J., Brock D.B., Ostfeld A.M., et al. Established Populations For Epidemiologic Studies of the Elderly: Resource Data Book. 1986;U.S. Government Printing Office, Washington, DC. NIH publication 86-2443.
27. Cornoni-Huntley J., Blazer D.G., Laffety M.E., et al. Established Populations For Epidemiologic Studies of the Elderly: Resource Data Book. Vol. 2:1990;U.S. Government Printing Office, Washington, DC. NIH publication 90-495.
28. Katz S., Akpom C.A. A measure of primary sociobiological functions. Int J Health Serv. 6:1976;493-508.
29. Nagi S.Z. An epidemiology measure of disability among adults in the United States. Milbank Q. 54:1976;439-467.
30. Rosow I., Breslau N. A Guttman health scale for the aged. J Gerontol Med Sci. 21:1966;556-559.
31. Fillenbaum G.G. Multidimensional Functional Assessment of Older Adults. The Duke Older Americans Resources and Services Procedures. 1988;Erlbaum, Hillsdale, NJ.
32. Spector W.D. Functional disability scales. Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. 1996;133-143 Lippincott-Raven, Philadelphia.
33. Rao K.M.K., Pieper C., Currie M.S., Cohen H.J. Variability of plasma IL-6 crosslinked fibrin dimers over time in community-dwelling subjects. Am J Clin Pathol. 102:1994;802-805.
34. Cox D.R. Regression models and life tables. J R Stat Soc B. 34:1972;187-202.
35. Frishman W.H. Biologic markers as predictors of cardiovascular disease. Am J Med. 104:1998;18-27.
36. Bittner V.B. Atherosclerosis and the immune system. Arch Intern Med. 158:1998;1395-1396.
37. Cushman M., Psaty B.M., Macy E., et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol. 16:1996;1163-1169.
38. Malek A.M., Alper S.L., Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 282:1999;2035-2042.
39. Kemper G., Myers A.M., Powell L.E. Hierarchical structure in ADL and IADL analytic assumptions and applications for clinicians and researchers . J Clin Epidemiol. 48:1995;1299-1305.
40. Taaffe D.R., Harris T.B., Ferrucci L., et al. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in the elderly MacArthur Studies of Successful Aging . J Gerontol Med Sci. 55A:2000;M709-M715.
41. Reuben D.B., Cheh A.I., Harris T.B., et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc. 50:2002;638-644.
42. Ershler W.B., Keller E.T. Age-associated increased interleukin-6 gene expression, late life diseases and frailty. Annu Rev Med. 51:2000;245-270.
43. Flier J., Underhill L.H. Protective and damaging effects of stress mediators. N Engl J Med. 338:1998;171-178.
44. Glaser R., Rabin B., Chesney M., et al. Stress-induced immunomodulation. JAMA. 281:1999;2268-2270.
45. Sorensen R.U., Butler B., Leiva L.E. A review of the immune system methodology for evaluating the impact of nutrition on its function . Suskin R.M., Tontisirin K. Nutrition, Immunity, and Infection in Infants and Children. 2001;55-68 Vevey/Lippincott Williams & Wilkins, Philadelphia.
46. Hamaguchi M., Morishita Y., Takahashi Y., et al. D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line. Blood. 77:1991;94-100.
47. Tapper H., Herwald H. Modulation of hemostatic mechanisms in bacterial infectious diseases. Blood. 96:2000;2329-2337.
48. Bone R.C. Immunologic dissonance a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS) . Ann Intern Med. 125:1996;680-687.
49. Shorr A.F., Trotta R.F., Alkins S.A., et al. D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease. Intensive Care Med. 25:1999;207-210.
50. Bernard G.R., Vincent J.l, Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709.